RNF168 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL18736370	0.51	1/20
SCHEMBL5992596	0.49	1/20
SCHEMBL18788822	0.49	1/20
SCHEMBL18818631	0.49	1/20
SCHEMBL10025880	0.49	1/20
SCHEMBL10025884	0.48	1/20
SCHEMBL26759489	0.47	1/20
SCHEMBL18007555	0.47	1/20
SCHEMBL19275220	0.47	1/20
SCHEMBL17727893	0.46	1/20
SCHEMBL28714921	0.46	1/20
SCHEMBL3864917	0.46	1/20
SCHEMBL10025883	0.46	1/20
SCHEMBL11896715	0.46	1/20
SCHEMBL28717337	0.46	1/20
SCHEMBL3863076	0.45	1/20
SCHEMBL12640962	0.45	1/20
SCHEMBL24974600	0.45	1/20
SCHEMBL13049455	0.45	1/20
SCHEMBL13079434	0.45	1/20

Clinical trials — most relevant to RNF168 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Cisplatin to Patients With Pancreatic Cancer and Homologous Recombination Deficiency	PHASE2/PHASE3	RECRUITING
Phase 2 Study Evaluating the Efficacy of the Combination of DKN-01 (DKK1 Inhibitor, Leap Therapeutics) and Pembrolizumab in the Treatment of Advanced or Recurrent Endometrial Cancer	PHASE2	ACTIVE_NOT_RECRUITING
Alrizomadlin (APG-115) in Subjects With BAP1 Cancer Syndrome and Early-Stage Mesothelioma	PHASE2	WITHDRAWN
Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent, in Subjects With BAP1 Cancer Predisposition Syndrome and Subclinical, Early-Stage Mesothelioma	PHASE2	SUSPENDED
Olaparib in Patients With HRD Malignant Mesothelioma	PHASE2	RECRUITING
Efficacy and Safety Study of Niraparib in Melanoma With Genetic Homologous Recombination (HR) Mutation	PHASE2	UNKNOWN
BRCA1-associated DNA Repair Dysfunction in Patients With Early Triple Negative Breast Cancer Treated With Neoadjuvant Platinum-based Chemotherapy	PHASE2	COMPLETED
A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001)	PHASE2	COMPLETED
Osimertinib and Etoposide as First-Line Treatment in Osimertinib-Resistant Advanced EGFR-Mutant NSCLC	PHASE2	NOT_YET_RECRUITING
Phase II ABT-888 With Cyclophosphamide	PHASE2	COMPLETED
Phase II Study of Olaparib and Pembrolizumab in Advanced Melanoma With Homologous Recombination (HR) Mutation	PHASE2	UNKNOWN
A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7248824 in Participants With Angelman Syndrome (AS)	PHASE1	COMPLETED
A Phase I Trial of SHR3162 in Subjects With Advanced Solid Tumors	PHASE1	COMPLETED
PS-341 and Radiation to Treat Advanced Cancer of the Head and Neck	PHASE1	COMPLETED
AZD2281 Plus Carboplatin to Treat Breast and Ovarian Cancer	PHASE1	COMPLETED
A Phase I Study of ABT-888, an Oral Inhibitor of Poly(ADP-ribose) Polymerase and Temozolomide in Children With Recurrent/Refractory CNS Tumors	PHASE1	COMPLETED
Long Term Follow-Up of Patients With Mesothelioma and Individuals With Germline Mutations in BAP1	nan	RECRUITING
The Role of RING Ubiquitin Ligases in Biologic and Oncologic Processes in Tissues of Mesenchymal Origin	nan	UNKNOWN
Differential Gene Expression of Liver Tissue and Blood From Individuals With Chronic Viral Hepatitis	nan	UNKNOWN
Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome	nan	RECRUITING
Prognostic Value of Combined Approach Based on KEAP1/NFE2L2 Mutations and Pre-therapeutic FDG-PET/CT Radiomic Analysis in Advanced Non-small-cell Lung Cancer PDL1 ≥ 50% Treated With Pembrolizumab (PEMBROMIC)	nan	UNKNOWN
Clinical Study of 68Ga-DOTA-BLP PET Imaging in Noninvasive Diagnosis of Malignant Tumors	nan	NOT_YET_RECRUITING
Prospective Evaluation of High Resolution Dual Energy Computed Tomographic Imaging, Noninvasive (Liquid) Biopsies, and Minimally Invasive Surgical Surveillance for Early Detection of Mesotheliomas in Patients With BAP1 Tumor Predisposition Syndrome	nan	RECRUITING
Genetics of Prostate Cancer in Young Patients	nan	COMPLETED
A Proof of Concept Study for the DNA Repair Driven by the Mesenchymal Stem Cells in Critical COVID-19 Patients	nan	COMPLETED
Impact of O6-methylguanine-DNA Methyltransferase (MGMT) Promoter Methylation and MGMT Expression on Dacarbazine Treated Sarcoma Patients (MGMT)	nan	UNKNOWN
Endocrine Disruptors and Life STILe in Breast Cancer Development	nan	UNKNOWN
Impact of Different BRCA1/2 Gene Variants on Response to Therapy and Prognosis of Ovarian Cancer	nan	RECRUITING
Germline Alterations of Tumor Susceptibility Genes in New York Cancer Patients	nan	ACTIVE_NOT_RECRUITING
Genes Contributing to Hereditary Ovarian Cancer in Women and BRCA1/2 Wildtype Families	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a RNF168 binder may also engage these)

Protein	Name	Similarity
Q0IIM1	—	1.000	Q0IIM1 →
B2RYR0	—	1.000	B2RYR0 →
Q80XJ2	—	1.000	Q80XJ2 →
B0BLU1	—	0.998	B0BLU1 →
Q6GNV6	—	0.997	Q6GNV6 →
Q80YR6	—	0.994	Q80YR6 →
Q6INS5	—	0.993	Q6INS5 →
Q4G163	—	0.993	Q4G163 →
Q9UKT4	—	0.992	Q9UKT4 →
PHF20	PHD finger protein 20	0.992	landscape →
Q9JIC3	—	0.992	Q9JIC3 →
Q6KAQ7	—	0.992	Q6KAQ7 →
Q90Z80	—	0.992	Q90Z80 →
Q6NZK5	—	0.992	Q6NZK5 →
Q58EL7	—	0.991	Q58EL7 →
Q9Y6A5	—	0.991	Q9Y6A5 →
Q09003	—	0.991	Q09003 →
Q6Y685	—	0.991	Q6Y685 →
Q69ZL1	—	0.991	Q69ZL1 →
Q2YDS5	—	0.991	Q2YDS5 →
B1WC58	—	0.990	B1WC58 →
Q8C115	—	0.990	Q8C115 →
A8MW92	—	0.990	A8MW92 →
Q58CQ0	—	0.990	Q58CQ0 →
Q9DAU9	—	0.990	Q9DAU9 →
P56273	—	0.990	P56273 →
Q2HJ46	—	0.990	Q2HJ46 →
Q80Y19	—	0.990	Q80Y19 →
E7FAP1	—	0.990	E7FAP1 →
A0P8Z5	—	0.990	A0P8Z5 →